DarioHealth (NASDAQ:DRIO) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of DarioHealth (NASDAQ:DRIO) from a hold rating to a sell rating in a report published on Saturday.

A number of other research analysts have also issued reports on DRIO. Weiss Ratings reissued a “sell (d-)” rating on shares of DarioHealth in a report on Monday, December 29th. Stifel Nicolaus set a $16.00 price objective on shares of DarioHealth in a research report on Friday, November 14th. Finally, Cowen restated a “hold” rating on shares of DarioHealth in a research note on Friday, November 14th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $32.00.

DarioHealth Price Performance

Shares of NASDAQ:DRIO opened at $10.52 on Friday. DarioHealth has a one year low of $5.93 and a one year high of $31.00. The stock has a market capitalization of $71.12 million, a price-to-earnings ratio of -0.94 and a beta of 1.05. The company has a 50-day simple moving average of $12.26 and a 200-day simple moving average of $12.18. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.02 and a current ratio of 4.55.

Institutional Investors Weigh In On DarioHealth

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd boosted its holdings in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,511 shares of the company’s stock after purchasing an additional 43,513 shares during the quarter. XTX Topco Ltd owned approximately 0.14% of DarioHealth worth $42,000 as of its most recent filing with the Securities and Exchange Commission. 33.39% of the stock is currently owned by hedge funds and other institutional investors.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.